CalciMedica, Inc. (NASDAQ:CALC – Get Free Report) insider Eric W. Roberts bought 53,333 shares of the company’s stock in a transaction on Friday, November 1st. The shares were bought at an average price of $3.75 per share, for a total transaction of $199,998.75. Following the completion of the acquisition, the insider now directly owns 164,706 shares in the company, valued at approximately $617,647.50. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link.
CalciMedica Stock Down 5.1 %
Shares of CALC opened at $3.51 on Friday. The stock has a market capitalization of $37.73 million, a P/E ratio of -2.51 and a beta of 1.30. CalciMedica, Inc. has a twelve month low of $2.14 and a twelve month high of $8.38. The company has a 50 day moving average of $4.25 and a 200-day moving average of $4.63.
CalciMedica (NASDAQ:CALC – Get Free Report) last released its earnings results on Monday, August 12th. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.03. On average, sell-side analysts anticipate that CalciMedica, Inc. will post -2.21 earnings per share for the current fiscal year.
Hedge Funds Weigh In On CalciMedica
Analyst Ratings Changes
CALC has been the topic of several research analyst reports. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of CalciMedica in a report on Tuesday, August 13th. Oppenheimer raised their price target on shares of CalciMedica from $14.00 to $20.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 10th.
Check Out Our Latest Stock Analysis on CALC
About CalciMedica
CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.
See Also
- Five stocks we like better than CalciMedica
- Business Services Stocks Investing
- Energy Vault Soars 100%: CEO Shares Why in MarketBeat Exclusive
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Meta’s Q3 Earnings Beat—Is This Dip a Golden Entry Opportunity?
- What Does a Stock Split Mean?
- Top Nuclear Stocks Thriving on Soaring Energy Demand
Receive News & Ratings for CalciMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CalciMedica and related companies with MarketBeat.com's FREE daily email newsletter.